SION
Sionna Therapeutics, Inc.NASDAQHealthcare$40.49-1.96%ClosedMarket Cap: $1.82B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.87
P/S
0.00
EV/EBITDA
-21.69
DCF Value
$1.23
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-22.9%
ROA
-23.1%
ROIC
-28.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-20.4M | $-0.46 |
| FY 2025 | $0.00 | $-75.3M | $-1.88 |
| Q3 2025 | $0.00 | $-20.3M | $-0.46 |
| Q2 2025 | $0.00 | $-18.1M | $-0.41 |
Analyst Ratings
View AllGuggenheimBuy
2026-03-03BTIGBuy
2026-03-02BTIGBuy
2026-01-14RBC CapitalUnderperform
2025-12-01Trading Activity
Insider Trades
View AllFitzpatrick Jenniferofficer: Chief Legal Officer
SellFri Mar 06
Fitzpatrick Jenniferofficer: Chief Legal Officer
SellFri Mar 06
Thompson Peter A.director
SellWed Feb 04
Thompson Peter A.director
SellWed Feb 04
ORBIMED ADVISORS LLCdirector
SellWed Feb 04
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
4.04
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.